publication date: Oct. 20, 2016
Non-Small Cell Lung Cancer Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status
Genentech said its pivotal phase III OAK study of Tecentriq (atezolizumab) showed a median survival of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.73, 95% CI: 0.62 – 0.87).
The results were presented at the European Society of Medical Oncology 2016 Annual Meeting in Copenhagen.
The OAK study evaluated people with non-small cell lung cancer whose disease had progressed on or after treatment with one or more platinum-based chemotherapy (second-line and third-line).
The study enrolled people regardless of their programmed death-ligand 1 (PD-L1) status and included both squamous and non-squamous disease types. Adverse events were consistent with those observed in previous Tecentriq studies.
“Tecentriq is the first and only anti-PD-L1 cancer immunotherapy to help people with metastatic NSCLC live significantly longer than chemotherapy regardless of their PD-L1 expression level or their disease histology,” Sandra Horning, chief medical officer and head of global product development, said in a statement. “Even people whose disease had low or no observed PD-L1 expression still showed a significant benefit from the medicine.”
Genentech is a member of the Roche Group.
FDA granted Breakthrough Therapy Designation for Tecentriq for the treatment of PD-L1-positive NSCLC … Continue reading CCL Oct 2016 – Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.